

## Highlights of This Issue 3493

### SPECIAL FEATURES

#### CCR Translations

- 3495 | **The Quest for Self-Identity: Not All Cancer Stem Cells Are the Same**  
Anita B. Hjelmeland and Jeremy N. Rich  
*See article p. 3628*

#### CCR New Strategies

- 3499 | **New Strategies in the Treatment of Mantle Cell Lymphoma**  
Changchun Deng, Sangmin Lee, and Owen A. O'Connor

#### CCR Drug Updates

- 3509 | **Romidepsin for Cutaneous T-cell Lymphoma**  
H. Miles Prince and Michael Dickinson

#### Molecular Pathways

- 3516 | **Molecular Pathways: Rodent Parvoviruses—Mechanisms of Oncolysis and Prospects for Clinical Cancer Treatment**  
Jürg P.F. Nüesch, Jeannine Lacroix, Antonio Marchini, and Jean Rommelaere

#### Review

- 3524 | **Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents**  
Martin Thurnher, Oliver Nussbaumer, and Georg Gruenbacher

### HUMAN CANCER BIOLOGY

- 3532 | **Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases**  
Anna Tamburrino, Alfredo A. Molinolo, Paolo Salerno, Rebecca D. Chernock, Mark Raffeld, Liqiang Xi, J. Silvio Gutkind, Jeffrey F. Moley, Samuel A. Wells, Jr. and Massimo Santoro

- 3541 | **Integrative Array-Based Approach Identifies MZB1 as a Frequently Methylated Putative Tumor Suppressor in Hepatocellular Carcinoma**  
Satoshi Matsumura, Issei Imoto, Ken-ichi Kozaki, Takeshi Matsui, Tomoki Muramatsu, Mayuko Furuta, Shinji Tanaka, Michiie Sakamoto, Shigeki Arai, and Johji Inazawa

### CANCER THERAPY: PRECLINICAL

- 3552 | **Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance**  
Grazia Ambrosini, Christine A. Pratilas, Li-Xuan Qin, Madhavi Tadi, Oliver Surriga, Richard D. Carvajal, and Gary K. Schwartz

- 3562 | **Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors**  
Margaret M. Centenera, Joanna L. Gillis, Adrienne R. Hanson, Shalini Jindal, Renea A. Taylor, Gail P. Risbridger, Peter D. Sutherland, Howard I. Scher, Ganesh V. Raj, Karen E. Knudsen, Trina Yeadon for the Australian Prostate Cancer BioResource, Wayne D. Tilley, and Lisa M. Butler

- 3571 | **Abiraterone Inhibits 3 $\beta$ -Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer**  
Rui Li, Kristen Evaul, Kamallesh K. Sharma, Kai-Hsiung Chang, Jennifer Yoshimoto, Jiayan Liu, Richard J. Auchus, and Nima Sharifi

- 3580 | **Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis**  
Christine M. Chan, Xia Jing, Laura A. Pike, Qiong Zhou, Dong-Jun Lim, Sharon B. Sams, Gregory S. Lund, Vibha Sharma, Bryan R. Haugen, and Rebecca E. Schweppe

3592 **Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells**

Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Kenji Kita, Takayuki Nakagawa, Shigeki Nanjo, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, Toshimitsu Uenaka, and Seiji Yano

3603 **Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma**

Zhijie Li, Shuang Yan, Navid Attayan, Sridevi Ramalingam, and Carol J. Thiele

3616 **LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF- $\beta$  and BMP-Associated Proinflammatory and Proangiogenic Signals**

Paul Flechsig, Monika Dadrich, Sebastian Bickelhaupt, Jürgen Jenne, Kai Hauser, Carmen Timke, Peter Peschke, Eric W. Hahn, Hermann-Josef Gröne, Jonathan Yingling, Michael Lahn, Ute Wirkner, and Peter E. Huber

## IMAGING, DIAGNOSIS, PROGNOSIS

3628 **Differential Expression of 2',3'-Cyclic-Nucleotide 3'-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival**

Michael Zorniak, Paul A. Clark, Heather E. Leeper, Matthew D. Tipping, David M. Francis, Kevin R. Kozak, M. Shahriar Salamat, and John S. Kuo  
*See commentary p. 3495*

3637 **Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non-Hodgkin Lymphoma**

Christina Heemann, Markus Kreuz, Irene Stoller, Nils Schoof, Frederike von Bonin, Marita Ziepert, Markus Löffler, Wolfram Jung, Michael Pfreundschuh, Lorenz Trümper, and Dieter Kube

3648 **Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy**

Andrea Salonia, Firas Abdollah, Umberto Capitanio, Nazareno Suardi, Alberto Briganti, Andrea Gallina, Renzo Colombo, Matteo Ferrari, Giulia Castagna, Patrizio Rigatti, and Francesco Montorsi

3658 **Increased miR-708 Expression in NSCLC and Its Association with Poor Survival in Lung Adenocarcinoma from Never Smokers**

Jin Sung Jang, Hyo-Sung Jeon, Zhifu Sun, Marie Christine Aubry, Hui Tang, Cheol-Hong Park, Fariborz Rakhshan, Debra A. Schultz, Christopher P. Kolbert, Ruth Lupu, Jae Yong Park, Curtis C. Harris, Ping Yang, and Jin Jen

3668 **Expression of Cocaine- and Amphetamine-Regulated Transcript Is Associated with Worse Survival in Small Bowel Carcinoid Tumors**

Kalle Landerholm, Liliya Shcherbina, Sture E. Falkmer, Johannes Järhult, and Nils Wierup

## CANCER THERAPY: CLINICAL

3677 **Prospective Study of Changes in the Metabolomic Profiles of Men during Their First Three Months of Androgen Deprivation Therapy for Prostate Cancer**

Philip J. Saylor, Edward D. Karoly, and Matthew R. Smith

3686 **Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival**

Yu Sawada, Toshiaki Yoshikawa, Daisuke Nobuoka, Hirofumi Shirakawa, Toshimitsu Kuronuma, Yutaka Motomura, Shoichi Mizuno, Hiroshi Ishii, Kohei Nakachi, Masaru Konishi, Toshio Nakagohri, Shinichiro Takahashi, Naoto Gotohda, Tadatashi Takayama, Kenji Yamao, Katsuhiko Uesaka, Junji Furuse, Taira Kinoshita, and Tetsuya Nakatsura

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3697 **Impact of MiRNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation**

Carlos Fernández de Larrea, Alfons Navarro, Rut Tejero, Natalia Tovar, Tania Díaz, María Teresa Cibeira, Laura Rosiñol, Gerardo Ferrer, Montserrat Rovira, María Rozman, Mariano Monzó, and Joan Bladé

**Genetic Variants in the PI3K/PTEN/  
AKT/mTOR Pathway Predict Head  
and Neck Cancer Patient Second  
Primary Tumor/Recurrence Risk  
and Response to Retinoid  
Chemoprevention**

Michelle A.T. Hildebrandt, Scott M. Lippman,  
Carol J. Etzel, Edward Kim, J. Jack Lee,  
Fadlo R. Khuri, Margaret R. Spitz,  
Reuben Lotan, Waun Ki Hong, and Xifeng Wu

## CORRECTIONS

3714


**Correction: Expansion of a CD8<sup>+</sup>  
PD-1<sup>+</sup> Replicative Senescence  
Phenotype in Early Stage CLL  
Patients Is Associated with Inverted  
CD4:CD8 Ratios and Disease  
Progression**

3715

**Correction: BRAF(V600) Inhibitor  
GSK2118436 Targeted Inhibition of  
Mutant BRAF in Cancer Patients  
Does Not Impair Overall Immune  
Competency**

## ABOUT THE COVER

Silencing of marginal zone B and B1 cell-specific protein (MZB1), a novel tumor suppressor gene for hepatoma, through CpG island methylation was independently associated with a worse outcome of patients with hepatocellular carcinoma, and restoration of MZB1 expression in hepatoma cells reduced cell proliferation *in vitro* and *in vivo*. Distribution of ectopically expressed FLAG-tagged MZB1 in HepG2 cells is shown by immunofluorescence analysis (red). An endoplasmic reticulum marker (Calnexin) and nuclei are also shown in green and blue (DAPI), respectively. For details, see the article by Matsumura and colleagues on page 3541 of this issue.



# Clinical Cancer Research

**18 (13)**

*Clin Cancer Res* 2012;18:3493-3715.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/18/13>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/18/13>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.